Jazz Pharmaceuticals, Inc. (JAZZ) Tops Q2 EPS by 5c; Guides FY11
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq edge higher ahead of midterm results; Apple falls
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $232.40 +8.38%
Financial Fact:
Net income (loss): 87.15M
Today's EPS Names:
INM, TRI, CRVL, More
Financial Fact:
Net income (loss): 87.15M
Today's EPS Names:
INM, TRI, CRVL, More
Join SI Premium – FREE
Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) reported Q2 EPS of $0.82, $0.05 better than the analyst estimate of $0.77. Revenue for the quarter came in at $64.6 million versus the consensus estimate of $61.86 million.
Sees FY2011 EPS of $3.15-$3.25, versus the consensus of $3.07.
Sees FY2011 EPS of $3.15-$3.25, versus the consensus of $3.07.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sotera Health Co. (SHC) Tops Q3 EPS by 2c; Offers Guidance
- Sysco Corp. (SYY) Reports In-Line Q1 EPS
- Jazz Pharmaceuticals (JAZZ) PT Raised to $275 at Barclays
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
